U.S. Wireless Telecom Stock News

Recent interest in ASP Isotopes (ASPI) has been driven by a U.S. District Court decision that allowed parts of a securities fraud class action to proceed, putting the company’s uranium enrichment claims under closer scrutiny. See our latest analysis for ASP Isotopes. The share price reaction around the court decision has come after a weak shorter term patch, with a 7 day share price return of 25.3% decline and a 90 day share price return of 28.1% decline. This is set against a 3 year total...

Earlier this month, American Airlines Group and its main operating subsidiary amended several large credit facilities, extending revolving credit and letter-of-credit maturities to March 5, 2031 while adding billions of dollars in incremental commitments and replacing prior facilities. This refinancing package gives American Airlines access to substantial committed liquidity for longer, which may matter as it contends with higher fuel costs, operational pressures, and a complex demand...

Investors may be wondering whether Verizon Communications at around US$49.48 is offering good value today, or if most of the opportunity is already priced in. The stock has had mixed short term moves, with a 2.3% decline over the last 7 days, a 1.1% return over 30 days, and gains of 22.1% year to date and 20.8% over the past year. Recent headlines have focused on Verizon Communications as a major US telecom operator, including ongoing commentary about its role in nationwide 5G deployment and...

Skyworks Solutions (SWKS) is back in focus after its Embedded World 2026 showcase, where it introduced new connectivity, isolation, timing, and power technologies aimed at AI-enabled embedded systems across multiple end markets. See our latest analysis for Skyworks Solutions. Despite the Embedded World 2026 announcements, recent share price momentum has been soft. The 30 day share price return is 12.93% and the 1 year total shareholder return is 17.41%, which points to fading sentiment after...

In 2025, Amneal Pharmaceuticals reported past annual results showing revenue of US$3.02 billion, operating income of US$421 million, and net leverage of 3.5x, alongside issuing mixed 2026 guidance with modest revenue growth but faster adjusted EBITDA and EPS growth expectations. A key insight is that the company’s outlook emphasizes higher-margin growth supported by biosimilars and new product launches, even as overall revenue guidance remains relatively restrained. We’ll now examine how...

Omnicom Group (NYSE:OMC) has completed its $13b acquisition of Interpublic Group. The company plans a major restructuring that includes 4,000 job cuts. Omnicom will consolidate several agency brands as part of its post deal integration. For investors tracking NYSE:OMC, this deal creates one of the largest combined marketing services groups, with a share price of $75.84 as of the last close. The stock is up 11.6% over the past 30 days, while the 5 year return stands at 18.5%. The integration...

Wondering whether Zillow Group at around US$44.89 is pricing in too much hope or not enough, this article focuses squarely on what the current share price implies about value. The stock has moved 10.0% over the past 7 days and 2.0% over the past 30 days. Yet year to date the return sits at a 31.6% decline, with a 35.2% decline over 1 year and a 65.8% decline over 5 years. Investors have been reacting to ongoing headlines around the US housing market, changing mortgage affordability and the...

In March 2026, Lantronix Inc. and Unusual Machines, Inc. announced a collaboration to co-develop next-generation autonomous drone components that combine Lantronix’s edge AI compute with Unusual Machines’ mission-critical flight control systems, aimed at U.S. defense, public safety, and commercial use cases under the US$1.10 billion Drone Dominance Program. The partnership’s modular, upgradeable architecture and focus on trusted domestic supply chains could make Unusual Machines a more...

TIC Solutions, Inc. has recently reported a fourth-quarter 2025 net loss of US$47.2 million and a full-year 2025 net loss of US$87.12 million, while also announcing a new CEO, Benjamin Heraud, a US$200 million share repurchase program, and fresh shelf registrations including an ESOP-related offering. The combination of deeper employee ownership via the ESOP-related share registration and a sizeable buyback plan highlights management’s commitment to capital returns and workforce alignment...

Viavi Solutions (NasdaqGS:VIAV) introduced Observer Threat Forensics, a cybersecurity and network analysis tool focused on NetSecOps convergence. The company plans to showcase Observer Threat Forensics at the RSA Conference, highlighting unified security and network visibility capabilities. For investors tracking Viavi Solutions, the move into threat forensics adds a new angle to a business already known for network test, monitoring, and visibility tools. Observer Threat Forensics shifts...

MarketAxess Holdings (MKTX) runs an electronic bond trading platform, giving institutional investors and dealers access to liquidity across corporate and government fixed income markets. The company reports annual revenue of about US$846.3m and net income of US$246.6m. See our latest analysis for MarketAxess Holdings. The share price has softened recently, with a 7 day share price return of 3.76% and a 1 month share price return of 1.74%. However, the 1 year total shareholder return of 18.5%...

CRISPR Therapeutics (CRSP) has moved back into focus after reporting strong commercial traction for its approved gene therapy CASGEVY, along with the completion of a US$600 million convertible note offering that lifts pro forma cash above US$2.5b. See our latest analysis for CRISPR Therapeutics. Despite recent news on CASGEVY and the new convertible notes, the share price has cooled, with a 30-day share price return of an 11.74% decline and a 1-year total shareholder return of 13.99%,...

Savara Inc. recently reported a US$32.24 million net loss for the fourth quarter of 2025, while also signing a new six-year headquarters lease in Yardley, Pennsylvania starting July 2026 with aggregate base rent of about US$1.78 million and five months of rent abatement. At the same time, the company advanced its lead therapy MOLBREEVI for autoimmune PAP, with the FDA confirming no advisory committee is planned and marketing applications progressing in Europe and the U.K., underscoring how a...

Kontoor Brands' Lee, part of NYSE:KTB, has launched an exclusive collaboration with J.Crew. The collection reimagines Lee's legacy denim styles with a fresh take on American classics. The capsule uses premium materials and is available for men, women, and kids through Lee.com and J.Crew. This is the first Lee collaboration spanning all age groups on Lee.com, signaling a shift toward a more premium, fashion forward positioning. Kontoor Brands, the owner of Lee and Wrangler, operates in a...

Earlier this week, Lindblad Expeditions reported a 23.3% year-on-year revenue increase and a strong EBITDA beat, but significantly missed analysts’ earnings-per-share estimates. This combination of robust top-line growth and weaker bottom-line performance has raised questions about how effectively the company is converting demand into sustainable profits. Next, we’ll explore how Lindblad’s strong revenue beat but weaker earnings performance could influence its investment narrative and future...

Earlier in March, RadNet, Inc. participated in Barclays’ Global Healthcare Conference and KeyBanc’s Healthcare Virtual Forum, where Executive Vice President and CFO Mark Stolper outlined the company’s plans across its outpatient imaging and digital health businesses. During these appearances, RadNet emphasized its push into radiology AI, highlighting the Gleamer acquisition as a key step in expanding its DeepHealth platform globally. We’ll now examine how RadNet’s AI-focused expansion,...

Constellation Brands, NYSE:STZ, has outlined new growth projects and marketing plans centered on its Pacifico beer brand as part of its 2027 strategy. The company is preparing targeted campaigns and new pack sizes around upcoming global events such as the World Cup, with an eye on volume recovery for Pacifico. Management has also indicated an adjustment to long term margin targets in response to shifting cost pressures and competition. For investors watching NYSE:STZ, the update comes with...

Akso Health Group (AHG) recently hit a new 52 week high at US$2.10, alongside reported 75.6% revenue growth and a 30% total return over the past year, despite a thin 1% gross margin. See our latest analysis for Akso Health Group. The latest move to US$2.42 comes after a strong run, with an 84.7% 1 month share price return and a 51.3% year to date share price return. The 1 year total shareholder return of 92.1% and very large 3 year total shareholder return suggest momentum has been building...

Resolute Holdings Management (RHLD) has drawn fresh attention after recent trading left the stock with a 9% decline over the past month and a 24% decline over the past three months, sharpening focus on its valuation profile. See our latest analysis for Resolute Holdings Management. Despite the recent 30 day and 90 day share price returns of 8.6% and 24.6% declines, respectively, the 1 year total shareholder return of about 3.7x and the latest $164.17 share price point to fading short term...

Accelerant Holdings (ARX) closed FY 2025 with fourth quarter revenue of US$326.9 million and a basic EPS loss of US$0.0027, while the trailing twelve month figures showed revenue of US$912.9 million and a basic EPS loss of US$7.49. Over recent periods, the company has seen quarterly revenue move from US$181.2 million in Q4 2024 to US$163.5 million in Q1 2025, US$204.7 million in Q2 2025, US$217.8 million in Q3 2025 and US$326.9 million in Q4 2025, with EPS shifting from US$10.57 in Q4 2024 to...

FDA approval sets new context for Protagonist Therapeutics The recent U.S. FDA approval of ICOTYDE for moderate to severe plaque psoriasis is a major regulatory milestone for Protagonist Therapeutics (PTGX). This development is putting fresh attention on the company’s commercial potential and broader pipeline. See our latest analysis for Protagonist Therapeutics. The FDA approval has arrived after a strong run in the shares, with a 23.31% 1 month share price return and a 91.67% 1 year total...

Lands' End (LE) has rounded out FY 2026 with Q4 revenue of US$462.4 million and basic EPS of US$0.40, supported by net income of US$12.3 million. Over recent quarters, the company has seen revenue move from US$261.2 million in Q1 2026 to US$317.5 million in Q3 2026 before reaching US$462.4 million in Q4. Quarterly EPS shifted from a loss of US$0.27 in Q1 to a profit of US$0.40 in Q4. For investors, the focus now is on how sustainable these earnings are given the thin trailing net profit...

Wondering if Jack Henry & Associates is priced attractively or already fully valued at around US$164 a share? This article breaks down what that current price might imply about the stock. The share price has moved by a 1.1% decline over the last week, a 3.7% gain over the last 30 days, and a 7.8% decline year to date, with a 4.9% decline over the last year and returns of 16.7% over three years and 14.6% over five years. That mix of shorter term weakness and longer term gains provides context...

If you are wondering whether Steel Dynamics at around US$167.56 is offering fair value or not, the key is to separate short term noise from the longer term valuation picture. The share price has seen a 4.3% decline over the last 7 days and a 12.7% decline over the last 30 days, even though the 1 year return sits at 34.2% and the 5 year return is 281.7%. Recent news coverage has focused on Steel Dynamics as a major US steel producer, with attention on how its capital allocation, capacity...